What are the effects and side effects of tazetostat?

Tazemetostat is an oral small molecule epigenetic regulatory targeted drug that mainly blocks the malignant transformation and spread of cancer cells by inhibiting EZH2 (enhancer Zeste homolog 2), a histone methyltransferase. This mechanism is different from traditional chemotherapy or immunotherapy. It is a major progress in the field of epigenetic research in recent years, and is especially suitable for some tumor patients with EZH2 gene mutations. The drug has demonstrated clinical efficacy in a variety of tumor types, especially in patients with epithelioid sarcoma (ES; soft tissue sarcoma) and EZH2-mutated follicular lymphoma (non-Hodgkin lymphoma).

In terms of therapeutic effect, tazerestat can effectively inhibit the activity of EZH2, block tumor cell proliferation signals, and normalize the differentiation of cancer cells. In some specific molecular types of malignant lymphomas or rare sarcomas, the treatment response is stable, and some patients can even achieve disease control for more than half a year or more. Because it is an oral preparation, it is more convenient to take and the treatment plan is flexible. It can be used as a single drug or in combination with other drugs.

Despite its clear targeting effect, tazerestat may still cause certain adverse reactions. The most common side effects mainly involve the blood system, including mild to moderate anemia, neutropenia, and thrombocytopenia, which may require regular blood routine monitoring to ensure safe medication. In addition, some patients may experience gastrointestinal-related discomforts such as fatigue, loss of appetite, nausea, constipation, and changes in taste. Most of these symptoms are controllable and reversible.

In addition, some patients may experience mild abnormalities in liver function, rash, or mild increased risk of infection, which is related to the drug's regulation of immune-related gene expression. It is worth noting that individual case reports suggest that it may have a teratogenic risk to the fetus, so female patients need to take effective contraceptive measures during treatment.

Reference materials:https://www.tazverik.com/